Stock Market Reviews

ERAS (Erasca, Inc.) News

Get the latest news, insights, and market updates on ERAS (Erasca, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Erasca (ERAS) Valuation Check After S&P Biotechnology Select Industry Index Inclusion
  Index inclusion puts Erasca stock on more investor radar screens Erasca (ERAS) was just added to the S&P Biotechnology Select Industry Index, a move that could steadily increase trading demand as index funds and benchmarked biotech portfolios adjust their holdings. See our latest analysis for Erasca. The index news lands on top of an already strong run, with the share price up 18.69 percent over the last month and an 89.50 percent 3 month share price return signaling building momentum, even...
  Dec 26, 2025 - $ERAS
• Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks
  As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are keenly observing potential opportunities across various sectors. While large-cap stocks often dominate headlines, penny stocks—typically smaller or newer companies—continue to pique interest due to their potential for significant returns when backed by solid financials. Despite being considered a relic of past trading days, penny stocks still offer intriguing prospects...
  Dec 12, 2025 - $ERAS
• Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results
  Erasca, Inc. (NASDAQ:ERAS) is one of the 12 hot penny stocks to invest in right now. On November 14, 2025, Erasca, Inc. (NASDAQ:ERAS) saw Guggenheim’s analyst Michael Schmidt reiterate a “Buy” rating with a $5 price target, following the company’s Q3 2025 results. The analyst highlighted key drivers, including recent Phase 1 trial initiations, additional […]
  Nov 29, 2025 - $ERAS
• Erasca to Present at the 8th Annual Evercore Healthcare Conference
  SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and
  Nov 25, 2025 - $ERAS
• 3 Promising Penny Stocks With Market Caps As Low As $200M
  As the Dow Jones Industrial Average reaches new heights, closing above 48,000 for the first time amid optimism about an end to the U.S. government shutdown, investors are keenly observing market dynamics that may influence their portfolios. Penny stocks, though a term from earlier market days, remain relevant as they often represent smaller or less-established companies with potential value. By focusing on those with strong financials and clear growth prospects, investors can uncover...
  Nov 13, 2025 - $ERAS
• Erasca Reports Third Quarter 2025 Business Updates and Financial Results
  U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $362 million as of September 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Nov. 1
  Nov 12, 2025 - $ERAS
• Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
  The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent a
  Nov 6, 2025 - $ERAS
• Erasca to Present at Upcoming Conferences in November
  SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim 2nd Annual Healthcare Innovation Conference (Novemb
  Nov 4, 2025 - $ERAS
• Discovering Potential: IZEA Worldwide And 2 Other Top Penny Stocks
  As U.S.-China trade tensions resurface, major stock indexes have posted significant weekly losses, highlighting the volatility in today's market. Despite this uncertainty, penny stocks—often smaller or newer companies—remain a relevant investment area for those seeking growth opportunities at lower price points. In this article, we explore three penny stocks that combine solid financial foundations with potential for impressive returns.
  Oct 13, 2025 - $ERAS
• Spotlight On September 2025's Promising Penny Stocks
  As the U.S. market continues to navigate a mixed landscape, with the Nasdaq reaching new highs while the Dow slips, investors are keeping a close eye on potential Federal Reserve interest rate cuts amidst inflation concerns. In this context, penny stocks—often seen as investments in smaller or newer companies—remain an intriguing area for those seeking growth opportunities at lower price points. By focusing on stocks that combine strong financial health with solid fundamentals, investors can...
  Sep 12, 2025 - $ERAS